Articles

The incidence of human papillomavirus (HPV)-associated oropharyngeal cancer is increasing. Patients treated for these cancers with radiation and chemotherapy are at increased risk for early and late side effects that diminish their quality of life, and nurses play a key role in coaching patients about living with these side effects. Read More ›

Real-world experience at The University of Texas MD. Anderson Cancer Center, Houston, showed that the most frequent immune-related adverse events leading to emergency department visits for patients treated with immune checkpoint inhibitors were diarrhea, colitis, pneumonitis, and dermatitis. Read More ›

One of the challenges of improving cancer care is the integration of genetic risk assessment into survivorship care. Read More ›

A pilot project to incorporate nurse navigation for all new patients diagnosed with a hematologic or gynecologic malignancy has met with success, improving access to care for patients at the Rutgers Cancer Institute of New Jersey (CINJ), as well as increasing patient and provider satisfaction. Read More ›

A growing number of patients treated at the infusion center, coupled with a fixed number of infusion chairs, helped to create a logjam at the National Cancer Institute–designated New York University Langone Medical Center. Read More ›

A recent project to implement a chemotherapy discharge class on a mixed medical oncology unit had encouraging results, according to Julianne Brogren, MS, RN, CNL, OCN, Clinical Nurse Leader, The University of Texas M.D. Anderson Cancer Center, Houston. Read More ›

Data suggest that greater than one-fourth of patients with estrogen receptor–positive metastatic breast cancer who are treated with an aromatase inhibitor (AI) will develop a mutation in the ESR1 gene, conferring resistance to the AI. Response after AI failure is poor, leading to a search for better therapeutic options.

Read More ›

Fulvestrant was found to extend progression-free survival compared with anastrozole in postmenopausal women with hormone receptor–positive locally advanced or metastatic breast cancer who have not received previous endocrine therapy. Read More ›

The use of the investigational CDK4/6 inhibitor abemaciclib, in combination with an aromatase inhibitor or with fulvestrant, or as monotherapy, has demonstrated efficacy in patients with HER2-negative/hormone receptor–positive breast cancer in multiple settings. Read More ›

Updated National Comprehensive Cancer Network guidelines for the management of breast cancer address the use of genomic expression profiling in predicting distant recurrence as well as the benefit of adjuvant endocrine therapy and adjuvant chemotherapy. Read More ›